Dataset Information


Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels.

ABSTRACT: Background:None of the current guidelines recommend antiviral therapy for inactive hepatitis B virus (HBV) carriers (IHCs). Methods:In this real-world, multicenter, nonrandomized study, 32 participants meeting the inclusion criteria were enrolled 1:1 for treatment with peginterferon ?-2b or monitoring without treatment based on participant preference. The expected treatment duration was 48 weeks. The primary end point was hepatitis B surface antigen (HBsAg) loss. The HBV vaccine could be injected after HBsAg loss. Results:All patients had HBsAg levels of <20 IU/mL. The mean baseline HBsAg levels were 6.6 IU/mL and 5.8 IU/mL in the treated and untreated groups, respectively. Fifteen (93.8%) participants achieved HBsAg loss, 5 obtained HBsAg seroconversion after undergoing a mean of 19.7 weeks of therapy in the treated group, and no one in the follow-up group achieved HBsAg loss during a mean follow-up time of 12.6 months (P < .0001). Generally, the therapy was well tolerated. Nine of 11 individuals who exhibited HBsAg loss benefited from receiving the HBV vaccine. Conclusions:This study provides justification for further studies of short-course peginterferon ?-2b for the functional cure of IHCs with low HBsAg levels. Additionally, HBV vaccine injection is beneficial after interferon-induced HBsAg loss.


PROVIDER: S-EPMC7324053 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5645387 | BioStudies
2018-01-01 | S-EPMC6049926 | BioStudies
2021-01-01 | S-EPMC7839551 | BioStudies
2019-01-01 | S-EPMC6590282 | BioStudies
2019-01-01 | S-EPMC6465180 | BioStudies
2019-01-01 | S-EPMC6783682 | BioStudies
2013-01-01 | S-EPMC3790882 | BioStudies
2018-01-01 | S-EPMC5902426 | BioStudies
2017-01-01 | S-EPMC5248511 | BioStudies
2019-01-01 | S-EPMC6541521 | BioStudies